Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway

  • Authors:
    • Ge Yu
    • Na Li
    • Yan Zhao
    • Wei Wang
    • Xiao‑Ling Feng
  • View Affiliations

  • Published online on: February 21, 2018     https://doi.org/10.3892/ol.2018.8090
  • Pages: 6513-6518
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Salidroside is one of the most potent compounds extracted from the plant Rhodiola rosea, and its cardiovascular protective effects have been studied extensively. However, the role of salidroside in human ovarian carcinoma remains unknown. The aim of the current study was to investigate the effects of salidroside on the proliferation and apoptosis of SKOV3 and A2780 cells using MTT assay and acridine orange/ethidium bromide staining. Salidroside activated caspase‑3 and upregulated the levels of apoptosis‑inducing factor, Bcl‑2‑associated X and Bcl‑2‑associated death promoter (Bad) proteins. Furthermore, salidroside downregulated the levels of Bcl‑2, p‑Bad and X‑linked inhibitor of apoptosis proteins. Salidroside activated the caspase‑dependent pathway in SKOV3 and A2780 cells, upregulating p53, p21Cip1/Waf1 and p16INK4a. These results suggest that the p53/p21Cip1/Waf1/p16INK4a pathway may serve a key function in salidroside-mediated effects on SKOV3 and A2780 cells. The current findings indicate that salidroside may be a promising novel drug candidate for ovarian cancer therapy.

Introduction

Ovarian cancer (OC) is the most lethal gynecological malignancy (1). For epithelial OC (EOC), the prognosis for premenopausal women with early-stage EOC is favorable (2). In the past few decades, patients with EOC were treated with the latest chemotherapeutic drugs and surgical techniques, but the 5-year survival rate was still ≤40% (3). A previous study reported that EOC demonstrates genomic instability (4). During treatment, numerous patients with EOC have recurrence and become resistant to chemotherapy, indicating that new treatment strategies are required (5,6). Therefore, numerous studies have been performed to identify effective therapeutic agents and their associated mechanisms of action (6,7).

Salidroside, a p-hydroxyphenethyl-β-D-glucoside (or phenylpropanoid glycoside), is one of the major active ingredients extracted from Rhodiola rosea and has a long history of use in Chinese medicine (811). Salidroside has primarily been used as a brain tonic, a roborant or headache relief agent (8,12). Recently, salidroside has been studied in experimental animals for its protective effects against hypoxia, cold, radiation and heavy physical exercise (11). It has been demonstrated that salidroside has various pharmacological properties (13), including antiaging (14), anticancer (15), anti-inflammation, hepatoprotective and antioxidative effects (16).

The aim of the current study was to investigate the effects of salidroside on OC, and to determine whether it may be a new therapeutic candidate in the treatment of OC.

Materials and methods

Cell culture

Human ovarian cancer cell lines, SKOV3 and A2780 from the American Type Culture Collection (Manassas, VA, USA), were cultured in RPMI 1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) containing 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in an incubator containing humidified air with 5% (v/v) CO2.

Cell viability assay

SKOV3 and A2780 cells were seeded in 96-well plates at 5×103 cells/well and treated with salidroside at different concentrations (0, 50, 100, 500, 1,000 or 2,000 µmol/l) for 48 h, at 37°C in an incubator containing humidified air with 5% (v/v) CO2. A total of 10 µl MTT (5 mg/ml) was added to each well and incubated in the dark at 37°C for 4 h. The supernatant was removed and replaced with 150 µl dimethyl sulfoxide. The plates were oscillated for 10 min and the absorbance was measured at 490 nm.

Acridine orange/ethidium bromide (AO/EB) staining

SKOV3 and A2780 cells in the logarithmic growth phase were deposited in 2×103 cells each well of a 96-well plate. After 24 h, cells were subsequently treated with salidroside (0 or 1,000 µmol/l) for 48 h at 37°C in an incubator containing humidified air with 5% (v/v) CO2, stained with AO (100 µg/ml in PBS) and EB (100 µg/ml in PBS) at room temperature and analyzed by fluorescence microscopy at ×200 magnification (17). Five fields were randomly selected for study. Cell apoptosis (%) was defined as the number of apoptotic cells divided by the total number of cells (18,19).

Antibodies and western blotting

SKOV3 and A2780 cells [treated with salidroside (1,000 µmol/l; salidroside group) or PBS (control group) for 48 h at 37°C in an incubator containing humidified air with 5% (v/v) CO2] were collected and lysed in ice-cold radioimmunoprecipitation assay buffer (Roche Diagnostics, Basel, Switzerland). The protein concentration of the lysates was measured using a bicinchoninic acid Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.) according to the protocol of the manufacturer. Cell lysates were separated by 10% SDS-polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose membranes (Pall Corporation, Port Washington, NY, USA). The membranes were blocked using 5% skim milk then incubated with primary antibodies against β-actin (cat. no. 3700; 1:2,000 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA), p53 (cat. no. 2524; 1:500 dilution; Cell Signaling Technology, Inc.), p21 Cip1/Waf1 (cat. no. 610233; 1:500 dilution; BD Biosciences, Franklin Lakes, NJ, USA), p16INK4a (cat. no. sc-53392; Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-2-associated X protein (Bax) (cat. no. 5020; 1:1,000 dilution; Cell Signaling Technology, Inc.), Bcl-2-associated death promoter (Bad) (cat. no. 9268; 1:500 dilution; Cell Signaling Technology, Inc.), and p-Bad (cat. no. 9291; 1:500 dilution; Cell Signaling Technology, Inc.), Bcl-2 (cat. no. 15071; 1:1,000 dilution; Cell Signaling Technology, Inc.), apoptosis-inducing factor (AIF) (cat. no. 5318; 1:1,000 dilution; Cell Signaling Technology, Inc.) and X-linked inhibitor of apoptosis (XIAP) (cat. no. 14334; 1:1,000 dilution; Cell Signaling Technology, Inc.) at 4°C overnight. The membranes were incubated with rabbit (cat. no. 7054; 1:5,000 dilution; Cell Signaling Technology, Inc.) or mouse (cat. no. 7056; 1:5,000 dilution; Cell Signaling Technology, Inc.) secondary antibodies at room temperature for 1.5 h. Immunoreactive bands were visualized using an enhanced chemiluminescence reagent (GE Healthcare, Chicago, IL, USA). Intensities of immunoreactive bands were determined by densitometric analysis using ImageJ software (version 1.61; National Institutes of Health, Bethesda, MD, USA) and normalized against β-actin.

Caspase-3 activity assay

A caspase-3 activity assay kit (cat no. C1115; Beyotime Institute of Biotechnology, Haimen, China) was used to test the activity of caspase-3 following treatment with salidroside (0 or 1,000 µmol/l) for 48 h in ovarian cancer (SKOV3 and A2780) cells. Caspase activity was expressed as a percentage of the control.

Statistical analysis

Data are presented as the mean ± standard error of the mean of three independent experiments. Statistical analysis was conducted using SPSS 19.0 software (IBM Corp., Armonk, NY, USA) and illustrated using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was determined using Student's t-test to compare two groups or analysis of variance with Tukey's post hoc test to compare multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Assessment of OC cell viability after treatment with salidroside

Across different concentrations (500, 1,000 or 2,000 µmol/l) of salidroside treatment, cell viability was significantly inhibited compared with the control (Fig. 1). The data revealed that salidroside treatment at 1,000 µmol/l for 48 h inhibited viability of SKOV3 and A2780 cells by ~50%. For this reason, in subsequent experiments 1,000 µmol/l was used as salidroside treatment.

Salidroside induces apoptosis in SKOV3 and A2780 cells

Cell viability is a balance between cell proliferation and apoptosis (20). AO/EB staining revealed that salidroside significantly increased the rate of apoptosis in SKOV3 (Fig. 2A) and A2780 cells (Fig. 2B).

Salidroside activates pro-apoptotic signaling pathways

To explore the functional mechanisms of salidroside, the expression of Bax, Bcl-2, Bad, p-Bad, AIF and XIAP proteins was investigated by western blotting in SKOV3 (Fig. 3A-E) and A2780 (Fig. 3F-J) cells. The results indicated that treatment with salidroside significantly upregulated the ratio of Bax/Bcl-2 and the expression of Bad and AIF, but significantly downregulated p-Bad and XIAP expression in SKOV3 and A2789 cells. Meanwhile, caspase-3 activity was significantly increased by salidroside in SKOV3 (2.1-fold increase) and A2780 (2.5-fold increase) cells.

Salidroside activates p53 signaling pathways

To define whether p53 signaling was involved in salidroside-induced apoptosis, the protein levels of p53, p21Cip1/Waf1 and p16INK4a were evaluated. They were identified to be significantly upregulated in SKOV3 (Fig. 4A-C) and A2780 (Fig. 4D-F) cells after treatment with salidroside compared with the control. These results indicated that the p53/p21Cip1/Waf1/p16INK4a pathway serves a critical function in salidroside-induced apoptosis in SKOV3 and A2780 cells.

Discussion

In the present study, in vitro experiments demonstrated that salidroside exerts potent anti-proliferative effects on SKOV3 and A2780 cells by inducing apoptosis. Furthermore, the mechanisms underlying the anticancer effects of salidroside on OC were investigated. The results indicated that activation of the caspase-3-dependent pathway and the p53 signaling pathway were involved in mediating these salidroside-induced effects. Therefore, the present results may provide an experimental basis for the potential role of salidroside in treating OC.

The current results are consistent with previous reports demonstrating that salidroside exerts anticancer effects in breast carcinoma (15), human fibrosarcoma (21,22) and neuroblastoma (23). The mechanism of action of salidroside has been reported to involve autophagy (24). However, the effect of salidroside in OC is not yet fully understood.

The present data suggested that salidroside has antiproliferative and pro-apoptotic effects on OC cells. It was revealed that salidroside inhibited the viability of SKOV3 and A2780 cells. Furthermore, AO/EB staining indicated that salidroside induced apoptosis in OC cells.

The effect of salidroside on the regulation of gene expression has been studied previously. Numerous studies have revealed that Bax, Bcl-2 and caspase-3 are involved in apoptosis in SKOV3 and A2780 cells (25). Liu et al (26) identified that caspase-mediated cleavage of Beclin1 inhibits autophagy and promotes apoptosis in SKOV3 cells. Furthermore, andrographolide radiosensitizes human SKOV3 cells (27), and miRNA-149 modulates the chemosensitivity of A2780 cells by modulating Bax protein expression (28). In the present study, it was demonstrated that salidroside could induce Bcl-2 and Bax expression, and upregulate caspase-3 in SKOV3 and A2780 cells. In addition, the ratio of Bcl-2/Bax was /decreased, indicating that salidroside promotes apoptosis in OC. Bad is known to regulate apoptosis by forming heterodimers with Bax and Bcl-2 (29). XIAP inhibits activation of caspases by binding to them, preventing apoptosis of tumor cells (30). In the present study, Bad protein was significantly increased while p-Bad and XIAP levels were significantly decreased following treatment with salidroside. These results demonstrate that salidroside could induce apoptosis via caspase-3-dependent apoptosis signaling in OC (31,32). Furthermore, p53 can influence apoptosis by regulating Bcl-2 (33). Previous studies have revealed that >50% of tumors are associated with p53 gene mutation; wild-type p53 gene therapy has been suggested to strengthen sensitivity to cisplatin in SKOV3 cells (3436). In the present study, it was demonstrated that salidroside has the ability to induce OC apoptosis. Salidroside also promoted the expression of p53, p21Cip1/Waf1 and p16 INK4a expression in SKOV3 and A2780 cells. It was identified that salidroside promotes the expression of caspase-3 and activation of the p53/p21Cip1/Waf1/p16INK4a pathway.

In summary, salidroside was demonstrated to reduce cell viability and promote apoptosis in OC. Furthermore, it was identified that salidroside activates caspase-3 and the p53/p21Cip1/Waf1/p16INK4a pathway. Therefore, salidroside is a promising new approach for the treatment of OC, but its underlying mechanism needs to be explored further.

Competing interests

The authors declare that they have no competing interests.

References

1 

Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Vang R, Shih IeM and Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 16:267–282. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Landen CN Jr, Birrer MJ and Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, et al: Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient centered endpoints in trials of maintenance therapy. Ann Oncol. Dec 18–2017.Doi: 10.1093/annonc/mdx796. View Article : Google Scholar

6 

Paik ES, Kim JH, Kim TJ, Lee JW, Kim BG, Bae DS and Choi CH: Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. J Gynecol Oncol. 29:e132018. View Article : Google Scholar : PubMed/NCBI

7 

Westin SN, Herzog TJ and Coleman RL: Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 31:213–229. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Jin N, Wu H, Miao Z, Huang Y, Hu Y, Bi X, Wu D, Qian K, Wang L, Wang C, et al: Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer. Sci Rep. 5:115662015. View Article : Google Scholar : PubMed/NCBI

9 

Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G and Wagner H: Rhodiola rosea in stress induced fatigue-a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine. 7:365–371. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Spasov AA, Wikman GK, Mandrikov VB, Mironova IA and Neumoin VV: A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine. 7:85–89. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Panossian A, Wikman G and Sarris J: Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 17:481–493. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Mao GX, Xing WM, Wen XL, Jia BB, Yang ZX, Wang YZ, Jin XQ, Wang GF and Yan J: Salidroside protects against premature senescence induced by ultraviolet B irradiation in human dermal fibroblasts. Int J Cosmet Sci. 37:321–328. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Barhwal K, Das SK, Kumar A, Hota SK and Srivastava RB: Insulin receptor A and Sirtuin 1 synergistically improve learning and spatial memory following chronic salidroside treatment during hypoxia. J Neurochem. 135:332–346. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Huang X, Zou L, Yu X, Chen M, Guo R, Cai H, Yao D, Xu X, Chen Y, Ding C, et al: Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. J Mol Cell Cardiol. 82:153–166. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Lai MC, Lin JG, Pai PY, Lai MH, Lin YM, Yeh YL, Cheng SM, Liu YF, Huang CY and Lee SD: Protective effect of salidroside on cardiac apoptosis in mice with chronic intermittent hypoxia. Int J Cardiol. 174:565–573. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Zhao G, Shi A, Fan Z and Du Y: Salidroside inhibits the growth of human breast cancer in vitro and in vivo. Oncol Rep. 33:2553–2560. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Yang ZR, Wang HF, Zuo TC, Guan LL and Dai N: Salidroside alleviates oxidative stress in the liver with non-alcoholic steatohepatitis in rats. BMC Pharmacol Toxicol. 17:162016. View Article : Google Scholar : PubMed/NCBI

18 

McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK and Green DR: The end of the (cell) line: Methods for the study of apoptosis in vitro. Methods Cell Biol. 46:153–185. 1995. View Article : Google Scholar : PubMed/NCBI

19 

Chen H, Takahashi S, Imamura M, Okutani E, Zhang ZG, Chayama K and Chen BA: Earthworm fibrinolytic enzyme: Anti-tumor activity on human hepatoma cells in vitro and in vivo. Chin Med J (Engl). 120:898–904. 2007.PubMed/NCBI

20 

Ribble D, Goldstein NB, Norris DA and Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 5:122005. View Article : Google Scholar : PubMed/NCBI

21 

Lambert KE, Huang H, Mythreye K and Blobe GC: The type III transforming growth factor-beta receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 22:1463–1472. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Lv C, Huang Y, Liu ZX, Yu D and Bai ZM: Salidroside reduces renal cell carcinoma proliferation by inhibiting JAK2/STAT3 signaling. Cancer Biomark. 17:41–47. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Hu X, Lin S, Yu D, Qiu S, Zhang X and Mei R: A preliminary study: The anti-proliferation effect of salidroside on different human cancer cell lines. Cell Biol Toxicol. 26:499–507. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Sun C, Wang Z, Zheng Q and Zhang H: Salidroside inhibits migration and invasion of human fibrosarcoma HT1080 cells. Phytomedicine. 19:355–363. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, Cao G and Wang Z: Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol. 564:18–25. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Liu Z, Li X, Simoneau AR, Jafari M and Zi X: Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog. 51:257–267. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Li X, Su J, Xia M, Li H, Xu Y, Ma C, Ma L, Kang J, Yu H, Zhang Z and Sun L: Caspase-mediated cleavage of Beclin1 inhibits autophagy and promotes apoptosis induced by S1 in human ovarian cancer SKOV3 cells. Apoptosis. 21:225–238. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Zhang C and Qiu X: Andrographolide radiosensitizes human ovarian cancer SKOV3 xenografts due to an enhanced apoptosis and autophagy. Tumour Biol. 36:8359–8365. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Zhan Y, Xiang F, Wu R, Xu J, Ni Z, Jiang J and Kang X: MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res. 8:482015. View Article : Google Scholar : PubMed/NCBI

30 

Huang C, Gu H, Zhang W, Herrmann JL and Wang M: Testosterone-down-regulated Akt pathway during cardiac ischemia/reperfusion: A mechanism involving BAD, Bcl-2 and FOXO3a. J Surg Res. 164:e1–e11. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Paulsen M, Ussat S, Jakob M, Scherer G, Lepenies I, Schütze S, Kabelitz D and Adam-Klages S: Interaction with XIAP prevents full caspase-3/-7 activation in proliferating human T lymphocytes. Eur J Immunol. 38:1979–1987. 2008. View Article : Google Scholar : PubMed/NCBI

32 

Xie Y, Tobin LA, Camps J, Wangsa D, Yang J, Rao M, Witasp E, Awad KS, Yoo N, Ried T and Kwong KF: MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene. 32:2442–2451. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, et al: KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J Pathol. 234:239–252. 2014.PubMed/NCBI

34 

Li YD, Hong YF, Yusufuaji Y, Tang BP, Zhou XH, Xu GJ, Li JX, Sun L, Zhang JH, Xin Q, et al: Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and −133 in patients with age-associated atrial fibrillation. Mol Med Rep. 12:3243–3248. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Gu J, Tang Y, Liu Y, Guo H, Wang Y, Cai L, Li Y and Wang B: Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cancer Lett. 343:200–209. 2014. View Article : Google Scholar : PubMed/NCBI

36 

Gherman C, Braicu OL, Zanoaga O, Jurj A, Pileczki V, Maralani M, Drigla F, Braicu C, Budisan L, Achimas-Cadariu P and Berindan-Neagoe I: Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis. Mol Cell Biochem. 413:189–198. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu G, Li N, Zhao Y, Wang W and Feng XL: Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway. Oncol Lett 15: 6513-6518, 2018
APA
Yu, G., Li, N., Zhao, Y., Wang, W., & Feng, X. (2018). Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway. Oncology Letters, 15, 6513-6518. https://doi.org/10.3892/ol.2018.8090
MLA
Yu, G., Li, N., Zhao, Y., Wang, W., Feng, X."Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway". Oncology Letters 15.5 (2018): 6513-6518.
Chicago
Yu, G., Li, N., Zhao, Y., Wang, W., Feng, X."Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway". Oncology Letters 15, no. 5 (2018): 6513-6518. https://doi.org/10.3892/ol.2018.8090